Table 1 Summary of participant demographics and baseline characteristics
From: A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI
ExPEC10V | Placebo | Total | |
|---|---|---|---|
N | 278 | 138 | 416 |
Age, mean (SD), years | 68.7 (6.16) | 69.1 (7.21) | 68.8 (6.52) |
Range | (60–88) | (60–86) | (60–88) |
60–64 years (%) | 90 (32.4) | 48 (34.8) | 138 (33.2) |
65–69 years (%) | 69 (24.8) | 30 (21.7) | 99 (23.8) |
70–74 years (%) | 71 (25.5) | 25 (18.1) | 96 (23.1) |
≥75 years (%) | 48 (17.3) | 35 (25.4) | 83 (20.0) |
Sex | |||
Female (%) | 220 (79.1) | 111 (80.4) | 331 (79.6) |
Male (%) | 58 (20.9) | 27 (19.6) | 85 (20.4) |
Race | |||
White (%) | 261 (96.0) | 129 (96.3) | 390 (96.1) |
Black/African American (%) | 7 (2.6) | 4 (3.0) | 11 (2.7) |
Asian (%) | 1 (0.4) | 1 (0.7) | 2 (0.5) |
American Indian/Alaska Native (%) | 1 (0.4) | 0 | 1 (0.2) |
Multiple (%) | 2 (0.7) | 0 | 2 (0.5) |
Ethnicity | |||
Not Hispanic or Latino (%) | 237 (85.3) | 117 (84.8) | 354 (85.1) |
Hispanic or Latino (%) | 38 (13.7) | 17 (12.3) | 55 (13.2) |
Not reported (%) | 3 (1.1) | 4 (2.9) | 7 (1.7) |
Body mass index, mean (SD), kg/m2 | 28.1 (4.60) | 27.6 (4.65) | 27.9 (4.61) |
Range | (19–39) | (19–38) | (19–39) |
